Results 51 to 60 of about 104,745 (290)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer

npj Precision Oncology, 2022
Carriers of germline BRCA2 pathogenic sequence variants have elevated aggressive prostate cancer risk and are candidates for precision oncology treatments.
Kevin H. Kensler, Shakuntala Baichoo, Shailja Pathania, Timothy R. Rebbeck   +3 more
doaj   +1 more source

The impact of known breast cancer polygenes on critical illness insurance [PDF]

, 2015
Genetic studies indicate that the inherited risk of breast cancer is mediated by the well-studied major genes BRCA1 and BRCA2, and a polygenic component, probably with many genes each making a small contribution. Recently, seven polygenes have been found
Adams, Craig, Donnelly, Catherine, Macdonald, Angus Smith   +2 more
core   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

Male breast cancer [PDF]

, 2017
Male breast cancer (MBC) is a rare disease representing less than 1% of all breast cancers (BC) and less than 1% of cancers in men. Age at presentation is mostly in the late 60s.
A Bjørnerem, A Holleb, A Jemal, AC Antoniou, AM Shaaban, B D'Avanzo, Breast Cancer Linkage Consortium, C Gómez-Raposo, C Martinez-Bouzas, C Rudlowski, D Albo, D Ly, D Palli, DA Rigoni-Stern, DG Evans, DS Popovic, E Kreiter, EF Lewison, G Masci, G Ribeiro, GR Brown, I Ganly, I Sosnovskikh, I Zanna, IS Fentiman, IS Fentinam, J Boyd, J White, JD Fackenthal, JH Breasted, JL Gnerlich, JR Weiss, K Coard, K Syrjakoski, KA Johansen Taber, KD Crew, L France, L Ottini, L Ottini, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Korde, M Falchetti, M Golshan, MA Adank, MB Cook, ME Meijer-van Gelder, MM Munoz de Toro, MT Vietri, N Orr, N Rahman, O Gentilini, P Karamanakos, RM Ferzoco, S Paik, S Peng, S Shak, S Thorlacious, SH Giordano, SH Giordano, SH Giordano, T Grenader, V Silvestri, V Silvestri, V Speirs, WF Anderson, WF Anderson, Y Ge, ZI Mitri   +71 more
core   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Niraparib in ovarian cancer. results to date and clinical potential [PDF]

, 2017
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi, Caruso, Davide, Papa, Anselmo, Tomao, Federica, Tomao, Silverio, Vici, Patrizia   +5 more
core   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in Cypriot population. [PDF]

, 2010
Inability to correctly repair DNA damage is known to play a role in the development of breast cancer. Single nucleotide polymorphisms (SNPs) of DNA repair genes have been identified, which modify the DNA repair capacity, which in turn may affect the risk
Bashiardes, E, Cariolou, MA, Daniel, M, Hadjisavvas, A, Kakouri, E, Loizidou, MA, Marcou, Y, Michael, T, Neuhausen, SL, Newbold, RF   +9 more
core  

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source